From the publisher
Healthcare professionals have turned to PDR "RM" for the latest word on prescription drugs for over 53 years! Today, PDR is still considered the standard prescription drug reference and can be found in virtually every physician's office, hospital and pharmacy in the United States. In fact, nine out of ten doctors consider PDR their most important reference source.
The 54th edition is over 3,000 pages with a larger, easier-to-read format that fits more information per page than ever before. You'll find the most complete data on over 4,000 drugs by generic and brand name, manufacturer, and product category. Some of the new listings for this edition include:
-- Xenical, the first of a new class of drugs called lipase inhibitors, indicated for obesity management.-- Agenerase, a new selective synthetic inhibitor of HIV-protease
-- Avandia, a new member of a class of antidiabetic agents which acts primarily by increasing insulin sensitivity in muscle and adipose tissue-- Celebrex and Vioxx, two new non-steroidal anti-inflammatory drugs
-- Enbrel, a new treatment option for rheumatoid arthritis-- Pletal, a phosphodieterase III inhibitor that reversibly inhibits platelet aggregation
The 2000 PDR also provides usage information and warnings, drug interactions, dosages, adverse reactions, pediatric use and all other FDA-required information. It also includes more than 2,100 full-size color photos cross-referenced to the drug.
